OXURION (EBR:OXUR) | Finanzwire

Basculer en Français

11053	Companies
242378	Keywords
170674	Articles
130468	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 10/03/2025 at 18:00, 11 months 19 days ago

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Atlas Special Opportunities, LLC converts 4 convertible bonds in Oxurion, leading to EUR 100,000 capital increase. Oxurion issues 5,990,086 new ordinary shares as part of EUR 20m Capital Commitment with Atlas. Company's total outstanding shares now 56,367,609

Shares Convertible Bonds Capital Increase Atlas Special Opportunities Oxurion
BRIEF

published on 10/02/2025 at 18:05, 11 months 20 days ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Actions Transparency Pharmaceutical Atlas Special Opportunities Oxurion
PRESS RELEASE

published on 10/02/2025 at 18:00, 11 months 20 days ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC regarding changes in shareholding. The company specializes in acquiring stakes in European pharmaceutical subcontractors. Risks associated with forward-looking statements and planned investments in digital assets are highlighted

Forward-looking Statements Digital Assets Transparency Notification Oxurion NV Pharmaceutical Subcontractors
BRIEF

published on 09/30/2025 at 18:05, 11 months 22 days ago

Oxurion 2025 Half-Year Results: Financial and Operational Analysis

Financial Results Digital Assets Forecasts Oxurion Pharmaceutical Subcontractors
PRESS RELEASE

published on 09/30/2025 at 18:00, 11 months 22 days ago

Oxurion Publishes First Half 2025 Results
Oxurion NV releases financial and business update for the six-month period ending June 30, 2025. The half-year report is available on the company's website. Oxurion specializes in acquiring pharmaceutical subcontractors

Acquisition Business Update Pharmaceutical Financial Update Oxurion NV
BRIEF

published on 09/16/2025 at 18:05, 1 year ago

Oxurion and Axiodis CRO leverage AI to revolutionize clinical trials

Artificial Intelligence Clinical Trials Oxurion Digital Twins Axiodis CRO
PRESS RELEASE

published on 09/16/2025 at 18:00, 1 year ago

Axiodis CRO, the French subsidiary of the Oxurion Group, announces a dual AI-driven strategic initiative to transform clinical trials
Axiodis CRO, a subsidiary of Oxurion NV, leverages AI to enhance clinical trials with digital twins for disease simulation and AI modules integrated into Exagis eCRF solution for improved data quality and workflow efficiency

AI Integration Clinical Trials Oxurion NV Digital Twins Axiodis CRO
BRIEF

published on 09/08/2025 at 18:05, 1 year ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Actions Transparency Atlas Special Opportunities Financial Risks Oxurion
PRESS RELEASE

published on 09/08/2025 at 18:00, 1 year ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notification from Atlas Special Opportunities II, LLC regarding change in shareholding. Oxurion specializes in acquiring majority stakes in European pharmaceutical subcontractors

Transparency Notification Shareholding Change Oxurion NV Belgian Transparency Legislation European Pharmaceutical Subcontractors
BRIEF

published on 09/01/2025 at 18:05, 1 year ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Actions Transparency Atlas Special Opportunities Oxurion Participation Thresholds

Accesswire

Published on 09/23/2026 at 00:00, 49 minutes ago

Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph(TM) Oncology Platform
Published on 09/23/2026 at 00:00, 49 minutes ago

Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph(TM) Oncology Platform
Published on 09/22/2026 at 23:10, 1 hour 39 minutes ago

Global Atomic Announces Proposed Public Offering of Units
Published on 09/22/2026 at 22:30, 2 hours 19 minutes ago

Silver Spruce Receives TSXV Conditional Approval of Debt Settlement
Published on 09/22/2026 at 22:01, 2 hours 48 minutes ago

Fermi and TensorWave Agree to Extend Closing Date to October 31, 2026

View all ACCESSWIRE

EQS Group

Published on 09/22/2026 at 19:40, 5 hours 8 minutes ago

EQS-Adhoc: Pyrum Innovations AG: Revision of the Forecast for the Financial Year 2026
Published on 09/22/2026 at 19:00, 5 hours 49 minutes ago

LLB focuses on its "elevate" strategy for growth, excellence and resilience
Published on 09/22/2026 at 18:30, 6 hours 19 minutes ago

Avolta partners with Hawaii’s Department of Transportation to expand airport dining at three airports
Published on 09/22/2026 at 17:45, 7 hours 4 minutes ago

Carvolix submits 510(k) for TAVIPILOT Robot, advancing toward US commercial launch of Its Integrated TAVIPILOT Platform.
Published on 09/22/2026 at 17:40, 7 hours 9 minutes ago

VALBIOTIS SA: Valbiotis announces positive results from the Cardio-Liver clinical study - Commercial launch of ValbiotisPRO® Foie on September 23

Les Echos

Published on 09/22/2026 at 18:10, 6 hours 39 minutes ago

Financial statements - 30 june 2026
Published on 09/22/2026 at 18:00, 6 hours 49 minutes ago

Consolidated results for the first half of 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 17:45, 7 hours 4 minutes ago

Imerys-09-2026-information-share-capital-and-voting-rights-as-of-31-August-2026
Published on 09/21/2026 at 18:19, 1 day 6 hours ago

Reporting on share buyback transactions carried out between September 14 and September 18, 2026
Published on 09/21/2026 at 18:01, 1 day 6 hours ago

Partnership agreement signed between Manitou Group and HD Construction Equipment

View all LES ECHOS COMFI WIRE